The recent availability of effective GLP-1R agonist (GLP-1RA) based treatments of obesity has provided great benefit to patients. Understanding the balance between body weight (BW) loss and nausea is paramount in predicting the effectiveness of GLP-1RA based medications, as is potential impact of delivery method. Quantitative systems pharmacology (QSP) modeling can aid in predicting both efficacy and adverse events of compounds, in particular assessing sources of similarities and differences between treatment protocols.